Overview
Top Medical Research Studies
Through the research, we found that intraperitoneal injections of vitamin C led to an increase in crucial proteins like Nrf2 and HO-1, which are known to help combat cancer. This process resulted in increased cell death in cancer cells through DNA damage and apoptosis, mimicking the effects seen when using pro-oxidant treatments in cells lacking the p53 protein—a critical tumor suppressor.
Furthermore, oral vitamin C not only activated these protective pathways but also spurred the expression of p53 in healthy tumor cells, showcasing its potential as an antimetastatic agent. We noted that vitamin C reduced the proliferation and migration of lung cancer cells while being gentler on normal cells, suggesting a safer therapeutic profile.
Overall, this study highlights vitamin C's dual role in both bolstering the body's defenses against cancer and directly inhibiting the spread of lung cancer, paving the way for its consideration in clinical treatments for pulmonary metastasis.
Interestingly, when we looked at all the studies together, we found no significant link between vitamin C intake—whether from food or supplements—and the risk of developing lung cancer. The overall analysis indicated a relative risk of 0.90, close to no effect at all.
However, our subgroup analysis revealed something noteworthy. We observed that individuals who consumed dietary vitamin C showed a significant decrease in lung cancer risk, with a relative risk of 0.82. On the other hand, supplementary vitamin C didn't provide any benefits, with a relative risk of 1.01, suggesting no protective effects.
This suggests that while vitamin C from our diet may help reduce lung cancer risk, vitamin C supplements are unlikely to have the same effect. We should consider focusing on dietary sources of this vitamin for potential lung health benefits.
Through our experiments, we observed that treatment with P-AscH causes oxidative stress in cancer cells. This stress leads to disruptions in their energy production, triggering a cascade of events that results in cell death and a decrease in their ability to survive cloning.
One key finding of our study is that P-AscH appears to target DNA and the cellular responses that repair DNA damage. We found that levels of DNA damage markers increased as a result of P-AscH treatment, while DNA repair mechanisms were found to be misaligned. Notably, using a substance called catalase alongside P-AscH reversed some of these damaging effects, indicating that hydrogen peroxide—a byproduct of P-AscH—plays a significant role in the process.
Overall, our research sheds light on the promising role of pharmacological ascorbate as a potential treatment for lung cancer. This could pave the way for new therapeutic strategies aimed at improving outcomes for patients with NSCLC.
Most Useful Reviews
Medical Researches
- All Researches
Our findings showed that when we pretreat lung cancer cells with high doses of vitamin C, they become more sensitive to the immune system's attacks. Specifically, we observed that vitamin C intensified the ability of CD8+ T cells—key players in the body's immune response—to destroy cancer cells. The results were particularly striking when vitamin C was combined with anti-PD1 therapy, significantly boosting tumor-killing effects and enhancing immune activity.
Additionally, our analysis revealed that vitamin C treatment altered various immune-related pathways, potentially improving the overall anti-tumor response. This suggests that high-dose vitamin C could serve as a valuable ally in lung cancer therapy, particularly in aiding the effects of established immunotherapies like anti-PD1.
The insights from this study could lead to new strategies for enhancing treatment options for patients battling lung cancer, promising a more effective approach in utilizing immune therapies.
Through the research, we found that intraperitoneal injections of vitamin C led to an increase in crucial proteins like Nrf2 and HO-1, which are known to help combat cancer. This process resulted in increased cell death in cancer cells through DNA damage and apoptosis, mimicking the effects seen when using pro-oxidant treatments in cells lacking the p53 protein—a critical tumor suppressor.
Furthermore, oral vitamin C not only activated these protective pathways but also spurred the expression of p53 in healthy tumor cells, showcasing its potential as an antimetastatic agent. We noted that vitamin C reduced the proliferation and migration of lung cancer cells while being gentler on normal cells, suggesting a safer therapeutic profile.
Overall, this study highlights vitamin C's dual role in both bolstering the body's defenses against cancer and directly inhibiting the spread of lung cancer, paving the way for its consideration in clinical treatments for pulmonary metastasis.
Importantly, we found that this dual approach did not harm normal lung cells, making it a promising strategy. Furthermore, when used together, RUC and vitamin C exhibited greater cancer-fighting properties than either agent alone. Our findings indicated that these treatments work synergistically, supporting the idea that a well-timed combination therapy could make standard treatments like chemotherapy more effective.
In experiments with NSCLC cells and tumor models, RUC and vitamin C showed substantial improvements in overall survival rates. This suggests that harnessing the unique oxidative environments of cancer cells can lead to enhanced anticancer effects. While our results are encouraging, it’s crucial to note that the study emphasized the specific combination's efficacy rather than isolated effects of vitamin C alone, leaving its independent role less clear.
Notably, we discovered two specific genes, SERPINE1 and SERPINB7, that showed reduced expression after vitamin C treatment. By linking patient data from our study and established databases, we found that low levels of these genes were associated with poorer survival outcomes in NSCLC patients receiving standard treatments. However, when patients included IVC alongside their standard care, higher levels of these genes correlated with longer overall survival.
These findings suggest that SERPINE1 and SERPINB7 could serve as potential biomarkers to predict how well patients respond to vitamin C treatments in addition to their usual care for lung cancer. While more research is needed to validate these results further, our exploration indicates promising avenues for enhancing treatment strategies in NSCLC.
Through our experiments, we observed that treatment with P-AscH causes oxidative stress in cancer cells. This stress leads to disruptions in their energy production, triggering a cascade of events that results in cell death and a decrease in their ability to survive cloning.
One key finding of our study is that P-AscH appears to target DNA and the cellular responses that repair DNA damage. We found that levels of DNA damage markers increased as a result of P-AscH treatment, while DNA repair mechanisms were found to be misaligned. Notably, using a substance called catalase alongside P-AscH reversed some of these damaging effects, indicating that hydrogen peroxide—a byproduct of P-AscH—plays a significant role in the process.
Overall, our research sheds light on the promising role of pharmacological ascorbate as a potential treatment for lung cancer. This could pave the way for new therapeutic strategies aimed at improving outcomes for patients with NSCLC.
User Reviews
- All Reviews
- Positive Reviews
- Negative Reviews
Frequently Asked Questions
Lung cancer is a type of cancer that begins in the lungs, which are vital organs located in the chest responsible for breathing and oxygen exchange. There are two primary types of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC accounts for about 85% of lung cancer cases and typically grows slower than SCLC, which is more aggressive and spreads quickly. Common risk factors for lung cancer include smoking, exposure to secondhand smoke, radon gas, and certain occupational hazards, making it essential to take preventive measures if you are at risk.
Symptoms of lung cancer can be subtle in the early stages, often including a persistent cough, chest pain, breathlessness, weight loss, and coughing up blood. Given that many individuals may not experience noticeable symptoms until the disease has progressed, regular check-ups and screenings are crucial, especially for those at higher risk. Treatment options for lung cancer may involve surgery, chemotherapy, radiation therapy, targeted therapy, or a combination of these approaches, depending on the cancer's type and stage. As research advances, new treatments are being developed, offering hope for improved survival rates and quality of life for those diagnosed.
Vitamin C, also known as ascorbic acid, is a water-soluble vitamin that plays a critical role in numerous bodily functions. As an essential nutrient, it contributes to the growth and repair of tissues in the body, and it is vital for the production of collagen, an important protein that helps maintain skin, cartilage, tendons, ligaments, and blood vessels. Additionally, Vitamin C acts as a powerful antioxidant, which means it helps combat free radicals—unstable molecules that can cause oxidative stress and contribute to various chronic diseases.
Moreover, Vitamin C enhances iron absorption from plant-based foods, making it a vital component for those following vegetarian or vegan diets. While many people get sufficient Vitamin C from a well-balanced diet that includes fruits and vegetables like oranges, strawberries, kiwi, broccoli, and bell peppers, some individuals might require supplementation. It's generally recommended to stay within the daily intake guidelines, as excessive consumption can lead to gastrointestinal disturbances. Overall, Vitamin C is not just a skincare celebrity—it's a fundamental part of maintaining overall health and well-being.
Based on user reviews, the timeline for seeing results when taking this supplement for lung cancer can vary widely, and specific timeframes are not universally mentioned. Users report that these capsules can be beneficial in enhancing overall health and potentially disrupting cancer cells, but they don’t provide definitive timelines for when results will be evident (Read Review).
Some users have shared that they incorporate the supplement into broader treatment plans, such as vitamin and ketone therapies, linking their expectations to the overall treatment strategy rather than just the supplement itself (Read Review). Overall, while many appreciate the positive effects they experience on their immune system and health in general, users do not specify a clear timeframe for results specifically related to lung cancer treatment, suggesting it may depend on individual circumstances and the specifics of one’s treatment regimen.
Research indicates that high-dose vitamin C may offer supportive benefits in lung cancer treatment, particularly enhancing the efficacy of established therapies like anti-PD1 and rucosopasem. A study found that pretreating lung cancer cells with vitamin C improved their sensitivity to immune system attacks, amplifying the tumor-killing effects of anti-PD1 therapy and boosting immune activity [1]. Another investigation suggested that when used alongside rucosopasem, vitamin C significantly improved treatment outcomes in non-small cell lung cancer (NSCLC), demonstrating a strong synergistic effect that increased overall survival rates [2].
Furthermore, vitamin C has shown potential in reducing lung cancer metastasis by promoting increased cell death in cancer cells while being gentler on normal cells [4]. While some studies report that dietary vitamin C may reduce lung cancer risk, evidence for the protective effects of vitamin C supplementation remains inconclusive [5]. Overall, while more research is necessary to fully establish vitamin C's role and efficacy in lung cancer treatment and prevention, existing studies suggest that it could be a valuable adjunct in multilayered treatment approaches for lung cancer patients.
Users have reported various improvements in their symptoms while using this supplement, particularly in the context of lung cancer treatment. For instance, one user noted that the capsules have been effective in disrupting cancer cells, highlighting their perceived benefits in combating lung cancer specifically (Read Review). Others have tied their experiences to broader treatment regimes, such as vitamin and ketone therapies, suggesting that the supplement may enhance the efficacy of these approaches in managing recurrent lung cancer (Read Review).
Additionally, some users mentioned improvements in overall immune function, noting an enhanced ability to fend off colds and infections while taking the supplement. One reviewer emphasized the importance of taking high doses and found that the capsules contributed positively to their immune system's resilience against both viral and bacterial challenges (Read Review). While individual results can vary, these anecdotal experiences suggest a range of potential benefits associated with this supplement in the context of lung cancer therapy and general wellness.
Users have reported mixed experiences when combining this supplement with other treatments in the context of managing lung cancer. Many have highlighted that the supplement works well alongside therapies such as vitamin and ketone treatments, suggesting a synergistic effect that may enhance overall effectiveness in combating cancer. One reviewer noted that their mother, undergoing vitamin and ketone therapy for recurrent lung cancer, was optimistic about the supplement’s role in her treatment, emphasizing its potential to disrupt cancer cells when administered intravenously (Read Review).
Additionally, some users emphasized the supplement's impact on immune support, noting that it helped them fend off infections and enhance resilience against health challenges, which is especially important for those undergoing cancer treatment (Read Review). One user found the supplement effective in this regard and appreciated its affordability and effectiveness against lung cancer specifically, indicating that it is well-regarded when integrated into broader wellness regimens (Read Review). Overall, users believe that while the specific combinations may vary, the supplement seems to offer complementary benefits alongside other therapies.
Research suggests that high-dose vitamin C, particularly in the form of pharmacological ascorbate, may be beneficial in treating lung cancer, especially when combined with established therapies like anti-PD1. This approach focuses on enhancing the immune response against non-small cell lung cancer (NSCLC). For example, a study indicated that high doses of vitamin C improved the sensitivity of lung cancer cells to immune system attacks, thus amplifying the tumor-killing effects of therapies like anti-PD1 [1]. Furthermore, delivering vitamin C intravenously has shown promising results in altering gene expressions linked to patient survival outcomes, indicating its potential as a valuable adjunct in lung cancer treatment [6].
It's also important to note that while combinations of vitamin C with other agents, such as the new drug rucosopasem, showed greater cancer-fighting properties, the exact optimal dose for independent vitamin C use remains unclear [2]. Moreover, a focus on the specific dose regimens used in studies has not been explicitly detailed, which suggests that further investigation is needed to define optimal dosing. As such, considering high doses of vitamin C alongside other treatment modalities appears to hold the most promise, but the precise quantities for safe and effective use still require more research for clear recommendations.
Our findings showed that when we pretreat lung cancer cells with high doses of vitamin C, they become more sensitive to the immune system's attacks. Specifically, we observed that vitamin C intensified the ability of CD8+ T cells—key players in the body's immune response—to destroy cancer cells. The results were particularly striking when vitamin C was combined with anti-PD1 therapy, significantly boosting tumor-killing effects and enhancing immune activity.
Additionally, our analysis revealed that vitamin C treatment altered various immune-related pathways, potentially improving the overall anti-tumor response. This suggests that high-dose vitamin C could serve as a valuable ally in lung cancer therapy, particularly in aiding the effects of established immunotherapies like anti-PD1.
The insights from this study could lead to new strategies for enhancing treatment options for patients battling lung cancer, promising a more effective approach in utilizing immune therapies.
Importantly, we found that this dual approach did not harm normal lung cells, making it a promising strategy. Furthermore, when used together, RUC and vitamin C exhibited greater cancer-fighting properties than either agent alone. Our findings indicated that these treatments work synergistically, supporting the idea that a well-timed combination therapy could make standard treatments like chemotherapy more effective.
In experiments with NSCLC cells and tumor models, RUC and vitamin C showed substantial improvements in overall survival rates. This suggests that harnessing the unique oxidative environments of cancer cells can lead to enhanced anticancer effects. While our results are encouraging, it’s crucial to note that the study emphasized the specific combination's efficacy rather than isolated effects of vitamin C alone, leaving its independent role less clear.
Through the research, we found that intraperitoneal injections of vitamin C led to an increase in crucial proteins like Nrf2 and HO-1, which are known to help combat cancer. This process resulted in increased cell death in cancer cells through DNA damage and apoptosis, mimicking the effects seen when using pro-oxidant treatments in cells lacking the p53 protein—a critical tumor suppressor.
Furthermore, oral vitamin C not only activated these protective pathways but also spurred the expression of p53 in healthy tumor cells, showcasing its potential as an antimetastatic agent. We noted that vitamin C reduced the proliferation and migration of lung cancer cells while being gentler on normal cells, suggesting a safer therapeutic profile.
Overall, this study highlights vitamin C's dual role in both bolstering the body's defenses against cancer and directly inhibiting the spread of lung cancer, paving the way for its consideration in clinical treatments for pulmonary metastasis.
Interestingly, when we looked at all the studies together, we found no significant link between vitamin C intake—whether from food or supplements—and the risk of developing lung cancer. The overall analysis indicated a relative risk of 0.90, close to no effect at all.
However, our subgroup analysis revealed something noteworthy. We observed that individuals who consumed dietary vitamin C showed a significant decrease in lung cancer risk, with a relative risk of 0.82. On the other hand, supplementary vitamin C didn't provide any benefits, with a relative risk of 1.01, suggesting no protective effects.
This suggests that while vitamin C from our diet may help reduce lung cancer risk, vitamin C supplements are unlikely to have the same effect. We should consider focusing on dietary sources of this vitamin for potential lung health benefits.
Notably, we discovered two specific genes, SERPINE1 and SERPINB7, that showed reduced expression after vitamin C treatment. By linking patient data from our study and established databases, we found that low levels of these genes were associated with poorer survival outcomes in NSCLC patients receiving standard treatments. However, when patients included IVC alongside their standard care, higher levels of these genes correlated with longer overall survival.
These findings suggest that SERPINE1 and SERPINB7 could serve as potential biomarkers to predict how well patients respond to vitamin C treatments in addition to their usual care for lung cancer. While more research is needed to validate these results further, our exploration indicates promising avenues for enhancing treatment strategies in NSCLC.
References
- Kim HS, Kwon SH, Choi OK, Lim T. High-dose ascorbic acid synergizes with anti-PD1 therapy in non-small cell lung cancer and models. Front Immunol. 2024;15:1512605. doi:10.3389/fimmu.2024.1512605
- Pulliam CF, Fath MA, Sho S, Johnson ST, Wagner BA, et al. Pharmacological ascorbate combined with rucosopasem selectively radio-chemo-sensitizes NSCLC via generation of HO. Redox Biol. 2025;80:103505. doi:10.1016/j.redox.2025.103505
- Munef A, Lafi Z, Shalan N. Investigating anti-cancer activity of dual-loaded liposomes with thymoquinone and vitamin C. Ther Deliv. 2024;15:267. doi:10.4155/tde-2023-0140
- Man S, Bi J, Liu F, Xie W, Ma L. Vitamin C Inhibited Pulmonary Metastasis through Activating Nrf2/HO-1 Pathway. Mol Nutr Food Res. 2024;68:e2300706. doi:10.1002/mnfr.202300706
- Tran DV, Luu XQ, Tran HTT, Myung SK. Dietary and supplementary vitamin C intake and the risk of lung cancer: A meta‑analysis of cohort studies. Oncol Lett. 2024;27:10. doi:10.3892/ol.2023.14144
- Ou J, Liao Q, Du Y, Xi W, Meng Q, et al. SERPINE1 and SERPINB7 as potential biomarkers for intravenous vitamin C treatment in non-small-cell lung cancer. Free Radic Biol Med. 2023;209:96. doi:10.1016/j.freeradbiomed.2023.10.391
- Sanookpan K, Chantaravisoot N, Kalpongnukul N, Chuenjit C, Wattanathamsan O, et al. Pharmacological Ascorbate Elicits Anti-Cancer Activities against Non-Small Cell Lung Cancer through Hydrogen-Peroxide-Induced-DNA-Damage. Antioxidants (Basel). 2023;12. doi:10.3390/antiox12091775
- Wang N, Ali A, Liu Z, Chi H, Lv Z, et al. Monofunctional dimetallic Ru(η6-arene) complexes inhibit NOTCH1 signaling pathway and synergistically enhance anticancer effect in combination with cisplatin or vitamin C. Eur J Med Chem. 2023;258:115536. doi:10.1016/j.ejmech.2023.115536
